Literature DB >> 20632856

Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types.

Zhaohui Ye1, Linzhao Cheng.   

Abstract

Human induced pluripotent stem (iPS) cells have been generated from various cell types including blood cells, and offer certain advantages as a starting population for reprogramming postnatal somatic cells. Unlike adult stem cells, iPS cells can proliferate limitlessly in culture while retaining their potential to differentiate into any cell type, including hematopoietic lineages. Derivation of patient-specific iPS cells, in combination with improved hematopoietic differentiation protocols, provides an alternative to generate histocompatible stem cells for bone marrow transplantation. In addition, the ability to reprogram blood cells and redifferentiate iPS cells back to hematopoietic lineages provides opportunities to establish novel models for acquired and inherited blood diseases. This article will summarize recent progress in human iPS cells derived from blood cells and hematopoietic differentiation from iPS cells. Advantages of blood as a source for reprogramming and applications in regenerative medicine will be discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20632856      PMCID: PMC4028827          DOI: 10.2217/rme.10.38

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  96 in total

1.  JAK2 mutations in myeloproliferative disorders.

Authors:  Ayalew Tefferi; Terra L Lasho; Gary Gilliland
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

2.  Differentiation of human embryonic stem cells into hematopoietic cells by coculture with human fetal liver cells recapitulates the globin switch that occurs early in development.

Authors:  Caihong Qiu; Eric Hanson; Emmanuel Olivier; Mari Inada; Dan S Kaufman; Sanjeev Gupta; Eric E Bouhassira
Journal:  Exp Hematol       Date:  2005-12       Impact factor: 3.084

3.  Some speculations on the myeloproliferative syndromes.

Authors:  W DAMESHEK
Journal:  Blood       Date:  1951-04       Impact factor: 22.113

4.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

7.  Identification of an acquired JAK2 mutation in polycythemia vera.

Authors:  Runxiang Zhao; Shu Xing; Zhe Li; Xueqi Fu; Qingshan Li; Sanford B Krantz; Zhizhuang Joe Zhao
Journal:  J Biol Chem       Date:  2005-04-29       Impact factor: 5.157

8.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

9.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

10.  Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture.

Authors:  M Bhatia; D Bonnet; U Kapp; J C Wang; B Murdoch; J E Dick
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

View more
  5 in total

Review 1.  Induced pluripotent stem cell (iPSCs) and their application in immunotherapy.

Authors:  Zhengping Jiang; Yanmei Han; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2013-12-16       Impact factor: 11.530

Review 2.  Pluripotent stem cell-based cancer therapy: promise and challenges.

Authors:  Saul J Sharkis; Richard J Jones; Curt Civin; Yoon-Young Jang
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

3.  Hematopoietic cells as sources for patient-specific iPSCs and disease modeling.

Authors:  Zhaohui Ye; Cyndi F Liu; Yoon-Young Jang
Journal:  Cell Cycle       Date:  2011-09-01       Impact factor: 4.534

4.  Mammalian genes induce partially reprogrammed pluripotent stem cells in non-mammalian vertebrate and invertebrate species.

Authors:  Ricardo Antonio Rosselló; Chun-Chun Chen; Rui Dai; Jason T Howard; Ute Hochgeschwender; Erich D Jarvis
Journal:  Elife       Date:  2013-09-03       Impact factor: 8.140

Review 5.  Chimeric Humanized Vasculature and Blood: The Intersection of Science and Ethics.

Authors:  Daniel J Garry; Arthur L Caplan; Mary G Garry
Journal:  Stem Cell Reports       Date:  2020-04-14       Impact factor: 7.765

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.